Published 2 months ago

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

T-Cells were genetically modified in a lab to recognize specific proteins on brain tumor cells.
CAR-T cells were modified to reprogram suppressor T-cells into killer T-cells to fight the tumor.
The modifications made T-cells more effective in battling cancer by outsmarting its ability to hide from detection.

Insights by Ground AI

Does this summary seem wrong?

0 Articles

All

Left

Center

Right

Associated Press News

A new strategy to attack aggressive brain cancer shrank tumors in two early tests - Seymour Tribune

WASHINGTON (AP) — A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients. Scientists took patients’ own immune cells and turned them into “living drugs” able to recognize and attack glioblastoma. In the first-step tests, those cells shrank tumors at least […]

2 months ago·United States

Read Full Article

abc News

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

Researchers revved up immune cells that shrank an extremely aggressive type of brain tumor when tested in a handful of patients

2 months ago·United States

Read Full Article

CNN

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

Three studies published within the past week have reported dramatic results with a therapy called CAR-T delivered directly to the brain. In some cases, tumors have seemingly melted away on brain scans by the next day.

2 months ago·Atlanta, United States

Read Full Article

The Washington Post

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

Researchers revved up immune cells that shrank an extremely aggressive type of brain tumor when tested in a handful of patients

2 months ago

Read Full Article

KRDO

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

By Brenda Goodman, CNN (CNN) — For decades, a diagnosis of glioblastoma – an aggressive, hard-to-treat cancer in the brain – has been a death sentence for patients. Only 3% to 5% of people who are diagnosed with this type of brain tumor will be alive three years later. On average, patients live about 14 months after diagnosis. Now, an experimental therapy that reprograms a person’s own immune cells to attack these tumors is showing some exciting…

2 months ago·Colorado Springs, United States

Read Full Article

KVIA

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

By LAURAN NEERGAARD AP Medical Writer WASHINGTON (AP) — Researchers revved up immune cells that shrank an extremely aggressive type of brain tumor when tested in a handful of patients. The experiments are just first steps but they signal a new strategy to fight hard-to-treat glioblastoma. It’s a twist on the CAR-T therapy already used to treat leukemia, by modifying patients’ own disease-fighting T cells to be better cancer hunters. Now Massachu…

2 months ago·Panama City, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left6Leaning Right2Center5Last Updated2 months agoBias Distribution

46% Left

Bias Distribution

46% of the sources lean Left

46% Left

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

0 Articles

0 Articles

A new strategy to attack aggressive brain cancer shrank tumors in two early tests - Seymour Tribune

A new strategy to attack aggressive brain cancer shrank tumors in two early tests - Seymour Tribune

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

A new strategy to attack aggressive brain cancer shrank tumors in two early tests

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics